IGHE and myeloid sarcoma: The present work revealed that after ILIT treatment, the quality of life of AR patients was markedly improved [SMD = ‐0.53, 95% CI = (‐1.00, ‐0.050)], and adverse events of nasal symptoms were reduced [RR = 0.16, 95% CI = (0.06, 0.45)], whereas there were no significant difference in SS [SMD = 0.14, 95% CI = (‐0.34, 0.62)], IgE [SMD = 0.93, 95% CI = (‐0.44, 2.30)], MS [SMD = 1.37, 95% CI = (‐0.45, 3.18)], CSMS [SMD = 0.93, 95% CI = (‐0.62, 2.47)], nasal symptoms [RR = 0.16, 95% CI = (0.06, 0.45)], and lymphadenopathy [RR = 2.27, 95% CI = (0.37, 6.73)] versus control.